Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Latest Information Update: 23 Feb 2023
Price :
$35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms GREKO III
- 21 Feb 2023 Status changed to completed.
- 13 May 2021 Status changed from active, no longer recruiting to discontinued.
- 22 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2021.